Is Astrazeneca Pharma India a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Astrazeneca Pharma India Ltd is a good quality company .

Is Astrazeneca Pharma India undervalued or overvalued?

The key valuation ratios of Astrazeneca Pharma India Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Astrazeneca Pharma India share price return in the past 10 years?

Astrazeneca Pharma India Ltd share price has appreciated 21.9% annually (CAGR) over the past ten years.

Is Astrazeneca Pharma India a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Astrazeneca Pharma India Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Astrazeneca Pharma India?

The latest standalone P/E ratio of Astrazeneca Pharma India as of 20-Sep-2024 is 178.97.

What is the P/B ratio of Astrazeneca Pharma India?

The latest standalone P/B ratio of Astrazeneca Pharma India as of 20-Sep-2024 is 24.62.

Astrazeneca Pharma India Ltd - Stock Valuation and Financial Performance

Name: Astrazeneca Pharma India
Brand: Astrazeneca Pharma India

BSE: 506820 | NSE: ASTRAZEN | Pharmaceuticals & Drugs | Small Cap

Place order

Astrazeneca Pharma I Share Price

₹6,862.75 134.75 2.00%
as on 20-Sep'24 16:01

10 Year X-Ray of Astrazeneca Pharma I:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	-12.9%	3.8%	18.7%	18.7%	26.5%	34.6%	31.2%	17.4%	24.5%	33.9%	-
Value Creation Index ⓘ	-1.9	-0.7	0.3	0.3	0.9	1.6	1.3	0.3	0.8	1.5	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	517	564	544	571	728	832	814	806	1,003	1,296	1,388
Sales YoY Gr.	-	9%	-3.6%	5%	27.6%	14.2%	-2.2%	-1%	24.5%	29.2%	-
Adj EPS ⓘ	-8.4	2.2	5.9	10.5	21.6	28.9	36.9	23.9	50.2	60.1	38.3
YoY Gr.	-	NA	171.6%	76.5%	106.5%	34.1%	27.4%	-35.2%	110.1%	19.8%	-
BVPS (₹) ⓘ	60.3	62.4	88.5	97.9	119.5	145.1	181.8	203.8	234.5	283.5	278.7
Adj Net Profit ⓘ	-21	5.5	14.8	26.1	54	72.3	92.2	59.7	126	150	96
Cash Flow from Ops. ⓘ	-45.7	57	38.1	8.8	55	87.4	105	101	58.3	27.9	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	10.7%	12.2%	16.8%	29.2%
Adj EPS ⓘ	NA	22.8%	17.7%	19.8%
BVPSⓘ	18.8%	18.9%	16%	20.9%
Share Price	21.9%	27.4%	30.3%	52.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	-13	3.6	7.8	11.1	19.7	21.7	22.5	12.3	22.8	23.1	13.6
Op. Profit Mgn % ⓘ	-2.6	3	6.9	8.2	9.8	14.6	16.7	10.7	16.5	14.3	11.2
Net Profit Mgn % ⓘ	-4.1	1	2.7	4.6	7.4	8.7	11.3	7.4	12.5	11.6	6.9
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	173	167	185	216	176	167	193	200	185	179	124
Cash Conv. Cycle ⓘ	11	17	11	12	0	-2	-1	6	4	23	71

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.78%

Net Profit is growing at healthy rate in last 3 years 17.73%

Sales growth is good in last 4 quarters at 29.98%

Return on Equity has declined versus last 3 years average to 13.60%

Latest Financials - Astrazeneca Pharma India Ltd.

	Standalone	Consolidated
TTM EPS (₹)	38.3	-
TTM Sales (₹ Cr.)	1,388	-
BVPS (₹.) ⓘ	278.7	-
Reserves (₹ Cr.) ⓘ	692	-
P/BV ⓘ	24.62	-
PE ⓘ	178.97	-

From the Market
52 Week Low / High (₹)	4050.15 / 7550.00
All Time Low / High (₹)	9.00 / 7550.00
Market Cap (₹ Cr.)	17,156
Equity (₹ Cr.)	5
Face Value (₹)	2
Industry PE ⓘ	47.6

Management X-Ray of Astrazeneca Pharma I:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Astrazeneca Pharma I

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Astrazeneca Pharma I

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	517	564	544	571	728	832	814	806	1,003	1,296
Operating Expenses ⓘ	531	547	507	525	657	711	678	719	838	1,111
Manufacturing Costs	26	33	44	59	58	49	57	65	82	94
Material Costs	194	195	171	178	227	300	287	305	355	590
Employee Cost	160	169	162	150	197	217	220	230	259	241
Other Costs ⓘ	150	150	129	137	175	146	115	119	142	185
Operating Profit ⓘ	-14	16	37	46	71	121	135	86	165	184
Operating Profit Margin (%)	-2.6%	2.9%	6.8%	8.1%	9.8%	14.5%	16.7%	10.7%	16.5%	14.2%
Other Income ⓘ	8	7	14	12	16	13	13	15	26	35
Interest ⓘ	0	0	0	0	0	1	1	1	1	1
Depreciation ⓘ	15	17	16	15	15	19	20	17	16	15
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	-40	16
Profit Before Tax ⓘ	-21	6	36	44	73	114	127	83	134	220
Tax ⓘ	0	1	15	18	18	42	34	21	35	58
Profit After Tax	-21	5	20	26	54	72	93	62	99	162
PAT Margin (%)	-4.0%	0.9%	3.7%	4.5%	7.5%	8.7%	11.5%	7.6%	9.9%	12.5%
Adjusted EPS (₹)	-8.3	2.1	8.0	10.4	21.8	28.9	37.3	24.6	39.7	64.6
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	3%	5%	41%	40%	37%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	151	156	221	245	299	363	455	509	586	709
Share Capital ⓘ	5	5	5	5	5	5	5	5	5	5
Reserves ⓘ	146	151	216	240	294	358	450	504	581	704
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	111	95	88	127	168	210	178	190	228	197
Others Liabilities ⓘ	150	178	205	203	124	203	241	277	328	372
Total Liabilities ⓘ	412	429	514	575	591	776	874	977	1,142	1,277
Fixed Assets
Gross Block	191	204	103	106	120	133	160	169	179	187
Accumulated Depreciation	90	106	16	30	45	61	79	94	110	120
Net Fixed Assetsⓘ	101	97	87	75	75	72	81	74	69	67
CWIP ⓘ	12	6	5	4	7	24	4	2	1	0
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	86	77	58	113	118	165	160	140	190	228
Trade Receivables	43	83	43	55	80	83	85	86	108	153
Cash Equivalents ⓘ	25	77	116	126	173	253	352	448	500	506
Others Assetsⓘ	144	89	206	203	138	179	192	226	274	323
Total Assets ⓘ	412	429	514	575	591	776	874	977	1,142	1,277

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	-46	57	38	9	55	87	105	101	58	28
PBT ⓘ	-21	6	36	44	73	114	127	83	134	220
Adjustment ⓘ	9	12	15	3	8	10	14	10	-5	-7
Changes in Working Capital ⓘ	-33	42	-0	-34	10	-3	-4	33	-30	-128
Tax Paid ⓘ	-1	-3	-12	-4	-35	-34	-33	-25	-41	-56
Cash Flow From Investing Activity ⓘ	-19	-4	0	-9	4	-171	173	5	18	22
Capex	-24	-9	-5	-6	-18	-14	-5	-6	-5	-10
Net Investments	0	0	0	-11	12	-169	169	0	0	0
Others ⓘ	5	5	6	8	11	12	9	11	23	32
Cash Flow From Financing Activityⓘ	0	-1	0	0	0	-6	-9	-9	-24	-44
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	-1	-1	-1	-1	-1
Dividend Paid ⓘ	0	0	0	0	0	-3	-5	-5	-20	-40
Others ⓘ	0	0	0	0	0	-3	-3	-4	-4	-4
Net Cash Flow ⓘ	-64	53	38	-1	59	-90	269	96	52	5

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	-12.93	3.43	10.63	11.12	20.03	21.83	22.83	12.78	18.13	24.95
ROCE (%)	-12.93	3.76	18.74	18.65	26.53	34.61	31.24	17.36	24.49	33.94
Asset Turnover Ratio	1.27	1.36	1.16	1.05	1.25	1.22	0.99	0.87	0.95	1.08
PAT to CFO Conversion(x)	N/A	11.4	1.9	0.35	1.02	1.21	1.13	1.63	0.59	0.17
Working Capital Days
Receivable Days	33	40	42	31	34	36	38	39	35	37
Inventory Days	63	52	45	55	58	62	73	68	60	59
Payable Days	208	193	194	220	238	230	247	220	215	131

Astrazeneca Pharma India Ltd Stock News

Astrazeneca Pharma India Ltd FAQs

What is the share price of Astrazeneca Pharma I?

Company share prices are keep on changing according to the market conditions. The closing price of Astrazeneca Pharma I on 20-Sep-2024 16:01 is ₹6,862.8.

What is the market cap of Astrazeneca Pharma I?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Sep-2024 16:01 the market cap of Astrazeneca Pharma I stood at ₹17,155.6.

What is the P/E ratio of Astrazeneca Pharma I?

The latest P/E ratio of Astrazeneca Pharma I as of 20-Sep-2024 16:01 is 179.0.

What is the P/B ratio of Astrazeneca Pharma I?

The latest P/B ratio of Astrazeneca Pharma I as of 20-Sep-2024 16:01 is 24.62.

What is the 52-week high and low of Astrazeneca Pharma I?

The 52-week high of Astrazeneca Pharma I is ₹7,550 and the 52-week low is ₹4,050.2.

What is the TTM revenue of Astrazeneca Pharma I?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Astrazeneca Pharma I is ₹1,388 ( Cr.) .

About Astrazeneca Pharma India Ltd

Astrazeneca Pharma India (AZPIL) incorporated on 11 July, 1979 is engaged in the business of manufacturing and marketing pharmaceutical products in healthcare segments namely gastrointestinal, cardiovascular, cancer, respiratory, neurosciences and infection. The company has an innovative portfolio in crucial areas of healthcare including cardiovascular, renal & metabolic diseases, oncology and respiratory. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is an indirect subsidiary of AstraZeneca PLC.

The company’s Global Technology Centre (GTC) in Chennai, is its primary insourced IT facility delivering significant value to the business through an end-to-end, integrated IT service delivery mode. The centre was set up in September 2014 in Chennai, Tamil Nadu, India with the mandate to deliver best in class IT service for the global business.

The company launched its R&D Bangalore in 2017 to support AstraZeneca’s global established medicines portfolio. The R&D Bangalore team provides support across a range of therapy areas, including oncology, respiratory and cardiovascular and metabolic diseases, with a focus on AstraZeneca’s mature brands which are used by patients around the world.

The Global Business Services (GBS), which now houses Global Commercial Operations (GCO), was set up in Chennai in 2017 and has driven efficiency across content management, multichannel marketing and analytics and reporting. GCO Global supports E2E commercial content management to markets - from creation, production, review, process, publishing and reporting. GCO helps multiple markets to avoid duplication of content leading to faster launches and cost savings.

Business area of the company

The Company is engaged in the business of manufacture, distribution and marketing of life-changing medicines in crucial areas of healthcare including oncology, cardiovascular, diabetes, renal, metabolic and respiratory.

Core Therapy Areas

Cardiovascular
Oncology
Respiratory

Milestones and achievements

1979: Astra IDL formation.
1982: Astra factory foundation.
1992: Launch of Cerviprime, Plendil, Ramace, Rhinocort and Imdur.
2001: Merger of Astra & Zeneca in 1999 globally, formed ‘AstraZeneca’ name in India in 2001.
2015: Launch of Forxiga.
2017: Launch of Tagrisso.
2018: Launch of Xigduo XR.
2018: Launch of first Metabolic Centre of Excellence in India.
2019: Launch of Lynparza.
2020: AstraZeneca India launches Qtern.